Industry News
Pharmaceutical Industry News
Vertex’s Trikafta pricing central to cystic fibrosis treatment disparities, study says
Vertex's Trikafta pricing central to cystic fibrosis treatment disparities, study says fkansteiner Mon, 02/14/2022 - 11:59
Pfizer and Regeneron led pharma’s sales growth in Q4 while Teva, Biogen and Gilead lagged
Pfizer and Regeneron led pharma's sales growth in Q4 while Teva, Biogen and Gilead lagged kdunleavy Mon, 02/14/2022 - 11:43
Novartis plots 400 job cuts in India after striking sales pact with Dr. Reddy’s
Novartis plots 400 job cuts in India after striking sales pact with Dr. Reddy's fkansteiner Mon, 02/14/2022 - 10:30
AstraZeneca pledges more Evusheld doses to US, bringing its antibody supply deal to $855M
AstraZeneca pledges more Evusheld doses to US, bringing its antibody supply deal to $855M fkansteiner Mon, 02/14/2022 - 09:47
Moderna eyes UK for next leg of mRNA vaccine manufacturing journey: report
Moderna eyes UK for next leg of mRNA vaccine manufacturing journey: report fkansteiner Mon, 02/14/2022 - 08:59
ASCO GU: J&J plays up precision therapy approach for Zejula’s prostate cancer bid after mixed results
ASCO GU: J&J plays up precision therapy approach for Zejula's prostate cancer bid after mixed results aliu Mon, 02/14/2022 - 05:05
Xanadu spins out of Yale with nasal COVID-19 vaccine tech, teeing up push to curb viral transmission
Xanadu spins out of Yale with nasal COVID-19 vaccine tech, teeing up push to curb viral transmission ntaylor Mon, 02/14/2022 - 04:38
Opiant’s nasal opioid overdose drug clears PK test, edges closer to FDA filing
Opiant's nasal opioid overdose drug clears PK test, edges closer to FDA filing ntaylor Mon, 02/14/2022 - 04:35
Covid Drugs May Work Well, but Our Health System Doesn’t
The people who need treatments the most may be the least likely to get them.
F.D.A. Clears Monoclonal Antibody Drug From Eli Lilly
The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness.
FDA signs off on Lilly’s new antibody drug, bebtelovimab, which is effective against the omicron variant
FDA signs off on Lilly's new antibody drug, bebtelovimab, which is effective against the omicron variant kdunleavy Fri, 02/11/2022 - 17:32
Pfizer’s and Lilly’s JAK inhibitor safety concerns prompt Europe to scrutinize drug class
Pfizer's and Lilly's JAK inhibitor safety concerns prompt Europe to scrutinize drug class kdunleavy Fri, 02/11/2022 - 15:33
Pfizer and Lilly’s JAK inhibitor safety concerns prompt Europe to scrutinize drug class
Pfizer and Lilly's JAK inhibitor safety concerns prompt Europe to scrutinize drug class kdunleavy Fri, 02/11/2022 - 15:33
Pfizer stalls COVID-19 vaccine app as it awaits data on third dose in young kids
Pfizer stalls COVID-19 vaccine app as it awaits data on third dose in young kids fkansteiner Fri, 02/11/2022 - 14:41
¿Vacunar a los niños pequeños o esperar?
No está claro si tres dosis de la vacuna Pfizer-BioNTech protegerán adecuadamente a los niños. Pero es posible que la FDA autorice las primeras dos dosis de cualquier manera.
FDA sets an example through Eli Lilly, Innovent’s PD-1, rocking the boat for future contenders: analyst
FDA sets an example through Eli Lilly, Innovent’s PD-1, rocking the boat for future contenders: analyst aliu Fri, 02/11/2022 - 11:28
Lumenis taps ‘This Is Us’ star Mandy Moore for first dry eye DTC campaign
Lumenis taps 'This Is Us' star Mandy Moore for first dry eye DTC campaign nmissakian Fri, 02/11/2022 - 09:37
Ipsen telegraphs $400M deal for consumer healthcare split
Ipsen telegraphs $400M deal for consumer healthcare split fkansteiner Fri, 02/11/2022 - 09:18
Lilly back in COVID-19 antibody game with $720 million deal with U.S. for omicron-busting hopeful
Lilly back in COVID-19 antibody game with $720 million deal with U.S. for omicron-busting hopeful kdunleavy Fri, 02/11/2022 - 09:17
Fierce Pharma Asia—Lilly, Innovent’s PD-1 saga; Biogen, Eisai’s Aduhelm rebuttal; Surprise FDA foreign inspections?
Fierce Pharma Asia—Lilly, Innovent’s PD-1 saga; Biogen, Eisai’s Aduhelm rebuttal; Surprise FDA foreign inspections? aliu Fri, 02/11/2022 - 06:55